Zanella M T, Baptista M, Costa C H, Kohlmann N E, Kohlmann Júnior O, Ribeiro A B
Eacola Paulista de Medicina-UFESP, São Paulo.
Arq Bras Cardiol. 1996 Jul;67(1):47-52.
To compare the effects of chlortalidone (CL) and captopril (Cp) upon glucose tolerance and serum insulin levels in essential hypertensive patients.
Non obese essential hypertensive patients with normal glucose tolerance test (OGTT) and diastolic blood pressure (DBP) > 90 mmHg and < or = 115 mmHg in the seated position were treated, in a randomized fashion, with Cp or CL during 16 weeks, after 16 weeks of placebo. The OGTT was performed after placebo and after active therapy, with serum insulin levels determinations carried out before and 120 minutes after oral glucose load.
Twenty four patients in the CL group and 19 in the Cp concluded the study. Hypocalemia (serum potassium < 3.8mEq/L or serum potassium reductions > or = 0.9mEq/ L) occurred in nine patients of the CL group (CL H). In this group CL therapy induced increments in the area under the curve of glycemia during OGTT (582 vs 610mg/h/dL, p < 0.05) that were not observed in the normocalemic patients of the CL (CLN) or Cp groups. Serum insulin levels during OGTT did not change with active therapy in all three groups. The insulin sensitivity index, however, decreased significantly in the CLH (1.9 vs 1.4; p < 0.05) and CLN (10.1 vs 4.3, p < 0.05) but remained unchanged in the Cp group (3.1 vs 2.5; NS). The insulin response to glucose index increased in the Cp (0.28 vs 0.40; p < 0.05) group but not in the CLH (0.25 vs 0.42; NS) and CLN (0.07 vs 0.24).
The antihypertensive therapy with chlortalidone in essential hypertensive patients may result in reductions in the peripheral sensitivity to insulin that can be accompanied by increases in glycemic levels after oral glucose load, particularly in patients who develop hypocalemia. Our results indicate that Cp therapy induces increments in insulin response to glucose without detectable changes in peripheral insulin sensitivity.
比较氯噻酮(CL)和卡托普利(Cp)对原发性高血压患者糖耐量和血清胰岛素水平的影响。
对糖耐量试验(OGTT)正常、坐位舒张压(DBP)>90mmHg且≤115mmHg的非肥胖原发性高血压患者,在安慰剂治疗16周后,随机给予Cp或CL治疗16周。在安慰剂治疗后和积极治疗后进行OGTT,并在口服葡萄糖负荷前及120分钟后测定血清胰岛素水平。
CL组24例患者和Cp组19例患者完成了研究。CL组9例患者(CL H)出现低钙血症(血清钾<3.8mEq/L或血清钾降低≥0.9mEq/L)。在该组中,CL治疗导致OGTT期间血糖曲线下面积增加(582对610mg/h/dL,p<0.05),而CL正常血钙患者(CLN)或Cp组未观察到这种情况。在所有三组中,OGTT期间的血清胰岛素水平在积极治疗后均未改变。然而,胰岛素敏感性指数在CL H组(1.9对1.4;p<0.05)和CLN组(10.1对4.3,p<0.05)显著降低,而在Cp组保持不变(3.1对2.5;无显著性差异)。Cp组胰岛素对葡萄糖指数增加(0.28对0.40;p<0.05),而CL H组(0.25对0.42;无显著性差异)和CLN组(0.07对0.24)未增加。
原发性高血压患者使用氯噻酮进行抗高血压治疗可能会导致外周胰岛素敏感性降低,并可能伴有口服葡萄糖负荷后血糖水平升高,尤其是在发生低钙血症的患者中。我们的结果表明,Cp治疗可诱导胰岛素对葡萄糖的反应增加,而外周胰岛素敏感性无明显变化。